WuXi PharmaTech Co., Ltd. Receives Letter From AAALAC Commending Animal Care at Suzhou Toxicology Facility as "Exemplary"

SHANGHAI, March 13, 2013 /PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that its Suzhou toxicology facility had received full accreditation from the Association for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC) after an extensive on-site evaluation. The AAALAC Committee on Accreditation commended the facility for "providing and maintaining an exemplary program of animal care." This represents AAALAC's highest level of commendation. The Suzhou facility first received accreditation from AAALAC in February 2010.

AAALAC is a private, nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. It evaluates all aspects of an animal care and use program, including institutional policies, animal husbandry, veterinary care and the physical plant. In its evaluations, it relies on widely accepted guidelines, such as the Guide for the Care and Use of Laboratory Animals and other reference resources, as well as its own position statements and Rules of Accreditation.

For more information, please contact:

Ronald Aldridge (for investors)
Tel: +1-201-585-2048
Email: ir@wuxiapptec.com

Aaron Shi (for the media)
Tel: +86-21-5046-4362
Email: pr@wuxiapptec.com

Web: http://www.wuxiapptec.com

SOURCE WuXi PharmaTech (Cayman) Inc.